TABLE 2.
Clinical features and treatment of CIP
| Overall N=60 | Nonrefractory CIP N=44 | Refractory CIP N=16 | P | |
|---|---|---|---|---|
| Time to CIP (wk), n (%) | — | — | — | 0.021 |
| ＜6 | 16 (26.7) | 8 (18.2) | 8 (50.0) | — |
| ≥6 | 44 (73.3) | 36 (81.8) | 8 (50.0) | — |
| CTCAE grade, n (%) | — | — | — | 0.211 |
| ≤2 | 36 (60.0) | 29 (65.9) | 7 (43.8) | — |
| >2 | 24 (40.0 | 15 (34.1) | 9 (56.2) | — |
| Symptoms, n (%) | — | — | — | 0.025 |
| Shortness of breath | 23 (38.3) | 12 (27.3) | 11 (68.8) | — |
| Cough | 21 (35.0) | 19 (43.2) | 2 (12.5) | — |
| Fever | 9 (15.0) | 6 (13.6) | 3 (18.8) | — |
| Others | 2 (3.3) | 2 (4.5) | 0 (0) | — |
| No symptoms | 5 (8.3) | 5 (11.4) | 0 (0) | — |
| Pneumonia, n (%) | — | — | — | 0.407 |
| Yes | 28 (46.7) | 22 (50.0) | 6 (37.5) | — |
| Suspicious | 6 (10.0) | 3 (6.8) | 3 (18.8) | — |
| No | 26 (43.3) | 19 (43.2) | 7 (43.8) | — |
| Starting dose of equivalent MP (mg/kg), n (%) | — | — | — | 0.121 |
| <1 | 9 (15.0) | 7 (15.9) | 2 (12.5) | — |
| 1-2 | 19 (31.7) | 17 (38.6) | 2 (12.5) | — |
| 2-3 | 17 (28.3) | 12 (27.3) | 5 (31.2) | — |
| ≥3 | 15 (25.0) | 8 (18.2) | 7 (43.8) | — |
| Antibiotic use, n (%) | — | — | — | 1.000 |
| Yes | 36 (60.0) | 26 (59.1) | 10 (62.5) | — |
| No | 24 (40.0) | 18 (40.9) | 6 (37.5) | — |
Statistically significant P values are in bold.
CIP indicates checkpoint inhibitor-related pneumonitis; CTCAE, Common Toxicity Criteria for Adverse Events; MP, methylprednisolone.